Investment Thesis
Achieve Life Sciences is a pre-revenue or near-zero revenue company with significant operating losses (-$39.8M) and negative free cash flow (-$31.5M), indicating the company is in early-stage development with no path to profitability yet visible. While the company maintains adequate liquidity ($31.9M cash) and low leverage, the burn rate relative to cash reserves suggests runway of approximately 12 months, requiring near-term capital raises or major commercialization progress.
ACHV Strengths
- Strong liquidity position with $31.9M in cash equivalents
- Low leverage with 0.00x debt-to-equity ratio
- Adequate working capital with 5.14x current ratio providing short-term financial flexibility
- Diagnostic substances sector offers potential for high-margin products upon commercialization
ACHV Risks
- Zero revenue generation indicates complete lack of commercialization despite company history
- Severe operating losses of $39.8M with negative $31.5M operating cash flow
- Cash runway approximately 12 months at current burn rate without revenue improvement
- Negative ROE (-119%) and ROA (-76.8%) indicate substantial destruction of shareholder value
- No demonstrated ability to generate cash from core operations
- Requires significant capital infusion or dramatic operational turnaround to survive
Key Metrics to Watch
- Quarterly revenue achievement and customer acquisition
- Operating cash flow trend and cash burn rate trajectory
- Cash reserves and timing of potential capital raises
- Product development milestones and regulatory approvals
- Insider buying/selling patterns indicating management confidence
ACHV Financial Metrics
Revenue
$0.0
Net Income
$-40.0M
EPS (Diluted)
$-0.99
Free Cash Flow
$-31.5M
Total Assets
$52.0M
Cash Position
$31.9M
ACHV Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-119.0%
ROA
-76.8%
FCF Margin
N/A
ACHV Balance Sheet & Liquidity
Current Ratio
5.14x
Quick Ratio
5.14x
Debt/Equity
0.00x
Debt/Assets
35.4%
Interest Coverage
-20.08x
Long-term Debt
N/A
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: Mar 19, 2026 |
Data as of: 2025-09-30 |
Powered by Claude AI